Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42

Benzinga · 1d ago
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $36 to $42.